Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA 6 Million IU/mL

Autor:	Beshoy Yanny, Nyan L. Latt, Antony Aziz, Mira Mikhail, Amanda Mitry, Sammy Saab, Amandeep Sahota, Ramy M Hanna, Francisco Durazo
Rok vydání:	2018
Předmět:	Ledipasvir Male medicine.medical_specialty Sofosbuvir Sustained Virologic Response Physiology Hepacivirus Gastroenterology Antiviral Agents California 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Medicine Humans 030212 general & internal medicine Aged Retrospective Studies Fluorenes business.industry Age Factors Retrospective cohort study Hepatitis C Middle Aged Viral Load medicine.disease Transplantation Regimen Treatment Outcome Tolerability chemistry 030211 gastroenterology & hepatology Benzimidazoles Female business Uridine Monophosphate Viral load medicine.drug
Zdroj:	Digestive diseases and sciences. 63(12)
ISSN:	1573-2568
Popis:	Results of recent studies have confirmed the efficacy of an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) in patients who are non-cirrhotics, native to treatment, are infected with hepatitis C (HCV) genotype 1, and have HCV viral load
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d65798784e6ba8e7d779272fc78daf68 https://pubmed.ncbi.nlm.nih.gov/30259281 Zobrazit plný text záznamu Full text from SpringerLink